Repositorio Dspace

Safety and Effectiveness of Subcutaneous Immunotherapy with an Undiluted Glutaraldehyde-Polymerized Pollen Extract Mixture in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Olive and Grass Pollen

Mostrar el registro sencillo del ítem

dc.contributor.author López-González, Paula
dc.contributor.author Padial-Vilchez, María-Antonia
dc.contributor.author Palomeque-Rodríguez, María-Teresa
dc.contributor.author Davila-Fernández, María-Galicia
dc.contributor.author Bellido-Linares, Virginia
dc.contributor.author Funes-Vera, Emilio
dc.contributor.author Cordobes-Duran, Conchita
dc.contributor.author Montoro-Ferrer, Ana
dc.contributor.author Moreno-Mata, Estefania
dc.contributor.author Villalobos-Violan, Victoria
dc.contributor.author Ortega-Martin, Laura
dc.contributor.author Gómez-Cardenosa, Aida
dc.date.accessioned 2026-11-11T09:07:15Z
dc.date.available 2026-11-11T09:07:15Z
dc.date.issued 2026-09-04
dc.identifier.citation López-González P, Padial Vilchez MA, Palomeque Rodríguez MT, Dávila-Fernández MG, Bellido Linares V, Funes Vera E, et al. Safety and Effectiveness of Subcutaneous Immunotherapy with an Undiluted Glutaraldehyde-Polymerized Pollen Extract Mixture in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Olive and Grass Pollen. Diseases. 4 de septiembre de 2026;14(9):321. doi:10.3390/diseases14090321
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29198
dc.description.abstract Background/Objectives: To evaluate the tolerability and effectiveness of subcutaneous immunotherapy (SCIT) with a glutaraldehyde-polymerized undiluted mixture of grass and olive pollen in adults and children with allergic respiratory disease in routine clinical practice. Methods: Observational, ambispective, controlled multicenter study including patients ? 5 years with allergic rhinitis/rhinoconjunctivitis +/? asthma due to olive and grass pollen. Patients initiating SCIT with Olea europaea/grass pollens undiluted mixtures were included in the O&G group, and those continuing symptomatic treatment in the untreated (UT) group. Safety (primary objective) was assessed as the incidence of adverse reactions. Effectiveness variables (symptoms, control, and medication use) were compared during the pollen season before and after AIT; patients and investigators reported perceived satisfaction. Results: We included 218 patients in the O&G group (children, 23.4%; adolescents, 13.8%; adults, 62.8%) with a mean (SD) age of 26.5 (15.6) years, and 94 in the UT group. At the time of evaluation, patients had received treatment for a mean (SD) of 10.6 (2.5) months. Seventeen patients (7.8%) experienced 18 adverse reactions in total, all local (12 in adults, 6 in children; mean overall rate: 0.8%). Rhinitis frequency shifted from predominantly persistent to intermittent (?64.6% in persistent) (p < 0.0001), with significantly improved intensity and control overall and across age groups in the O&G group but not in the UT group. Patients with asthma symptoms decreased by ?46.6% (p < 0.0001), along with improved asthma classification, treatment steps, and control overall (O&G group), and across most age groups. Changes in conjunctivitis symptoms followed a similar trend. Symptomatic medication use significantly decreased overall (O&G group) and across specific age groups. Patients and investigators perceived decreased symptoms and medication use after AIT. Conclusions: SCIT with a glutaraldehyde-polymerized undiluted allergen mixture of olive/grass pollen extract demonstrated safety and effectiveness to treat allergic rhinitis and asthma in adults and children in a real-world setting.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Safety and Effectiveness of Subcutaneous Immunotherapy with an Undiluted Glutaraldehyde-Polymerized Pollen Extract Mixture in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Olive and Grass Pollen
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://www.mdpi.com/2079-9721/14/9/321
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.3390/diseases14090321
dc.journal.title Diseases
dc.identifier.essn 2079-9721


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta